Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* subjects aged 3 months old at the date of recruitment;~* with informed consent signed by parent(s) or guardians;~* parent(s) or guardians are able to attend all planned clinical appointments and~* obey and follow all study instructions;~* subjects have not been vaccinated with IPV vaccine, OPV vaccine, DTP vaccine and related vaccines;~Exclusion Criteria:~* subject who has a medical history with hypersensitiveness, eclampsia, epilepsy, cerebropathy and neurological illness;~* allergic to any ingredient of vaccine or with allergy history to any vaccine;~* subjects with immunodeficiency or suspected impairment of immunologic function (e.g. caused by HIV), or subjects are in the process of immunosuppressor therapy(Taking orally injecting of steroid hormone);~* administration of immunoglobulins within 30 days prior to this study;~* acute febrile disease(temperature ≥ 37.0°C) or infectious disease;~* have a clearly diagnosed history of thrombocytopenia or other coagulopathy,~* may cause contraindications for subcutaneous injection;~* any serious chronic illness, acute infectious diseases, or respiratory diseases;~* severe cardiovascular disease, liver and kidney diseases or diabetes mellitus with complications;~* any kind of infectious, purulent, or allergic skin diseases;~* any other factor that makes the investigator determines the subject is unsuitable for this study.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 3 Months
- Healthy Volunteers: t

Study Arms:
- Sabin-IPV and DTaP (Type: EXPERIMENTAL): 234 subjects are simultaneously administrated with Sabin-IPV and DTaP at the age of 3/4/5 months old, 0.5 ml each dose, respectively
- Sabin-IPV only (Type: ACTIVE_COMPARATOR): 234 subjects are administrated with Sabin-IPV only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
- DTaP only (Type: ACTIVE_COMPARATOR): 234 subjects are administrated with DTaP only at the age of 3/4/5 months old, 0.5 ml each dose, respectively

Based on this trial design, predict the completion outcome and termination type (if applicable).